中文名稱

ABT-869 (50 mg)

英文名字

Linifanib, ABT-869, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N

供應(yīng)商

Cayman

產(chǎn)品貨號(hào)

13653-50

產(chǎn)品報(bào)價(jià)

￥29890/50 mg

產(chǎn)品說(shuō)明書

點(diǎn)擊查看

購(gòu)買方式

產(chǎn)品新聞

背景資料

Receptor tyrosine kinases -RTKs) mediate critical signaling transduction pathways important for cell survival, growth, and differentiation. Whereas aberrant tyrosine kinase signaling is correlated with the progression of various cancers, RTK inhibitors are useful as cancer therapy agents. ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor -VEGF) and platelet derived growth factor -PDGF) receptor families -e.g., KDR, Flt1, Flt3, Flt4, CSF-1R, and KIT) demonstrating IC50 values ranging from 4-190 nM. ABT-869 shows little activity against unrelated RTKs, cytoplasmic tyrosine kinases, or Ser/Thr kinases -IC50s > 1 uM). ABT-869 inhibits proliferation in MV-4-11 and MOLM-13 cells -acute myeloid leukemia cell lines harboring RTK mutations; IC50s = 4 and 6 nM, respectively), inducing apoptosis as evidenced by an increased sub-G0/G1 phase cell population, caspase activation, and PARP cleavage. In murine xenograft models, as well as in a phase 1 clinical trial, ABT-869 demonstrated respectable efficacy in solid tumors including lung and hepatocellular carcinomas.

產(chǎn)品描述

An ATP-compeitive, multi-targeted RTK inhibitor that inhibits all members of the VEGF and PDGF receptor families -IC50s = 4-190 nM); inhibits proliferation in MV-4-11 and MOLM-13 cells -IC50s = 4 and 6 nM, respectively)

產(chǎn)品形式

保存建議

-20

其他

Cayman Chemical

注意

該頁(yè)面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說(shuō)明書為準(zhǔn)。下單前，請(qǐng)瀏覽說(shuō)明書確認(rèn)。

分享到：